Skip to main content

Table 4 Neurodevelopmental outcomes at 18 months of age (N = 8)

From: Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility

 

N (%)

Severe neurodevelopmental disability

3 (38)

CP (GMFCS levelV)

2 (25)

Cognitive and language delay

1 (13)

Mild neurodevelopmental disability

0 (0)

Normal neurodevelopmental findings

5 (62)

  1. CP cerebral palsy, GMFCS Gross Motor Function Classification System